Grigori Okoev, MD
Hematology & Oncology · York, PANPI 1346635679
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 28.4% of the total. 2025 is the largest year on record at $288, 4.0 times the $72 reported in 2022. That places this record below the midpoint for hematology & oncology clinicians in PA, where the typical reported total is $1,277.
Across 27 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$160
- Accord Healthcare, Inc.$89
- Gilead$63
- AstraZeneca$40
- Rigel Pharmaceuticals, Inc.$32
- Bristol Myers Squibb$31
- plus $148 from 7 others
Across 4 payments — averaging $33,461 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$109K
- AstraZeneca$25K
What the payments were for
- Food & beverage$563100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 6 | $160 |
| Accord Healthcare, Inc. | 1 | $89 |
| Gilead(2 entities) | 2 | $63 |
| AstraZeneca(2 entities) | 3 | $40 |
| Rigel Pharmaceuticals, Inc. | 3 | $32 |
| Bristol Myers Squibb | 2 | $31 |
| GSK | 1 | $30 |
| Sanofi | 2 | $28 |
| Fennec Pharmaceuticals, Inc. | 3 | $26 |
| Spectrum Pharmaceuticals Inc. | 1 | $19 |
| Incyte Corporation | 1 | $18 |
| Array Biopharma Inc | 1 | $14 |
| Fresenius Kabi USA, LLC | 1 | $13 |
How this compares
$563 in reported general payments places this provider in the 35th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 11 | $125,888 |
| EliquisApixaban | 38 | $27,217 |
| Abiraterone Acetate | 14 | $20,165 |
| Anastrozole | 155 | $2,331 |
| Dexamethasone | 122 | $1,152 |
| Prochlorperazine Maleate | 97 | $974 |
| Tamoxifen Citrate | 19 | $682 |
| Letrozole | 22 | $631 |
| Gabapentin | 28 | $550 |
| Acyclovir | 49 | $540 |
| Hydroxyurea | 24 | $393 |
| Oxycodone Hcl | 19 | $345 |
| Pantoprazole Sodium | 21 | $269 |
| Prednisone | 64 | $255 |
| Alendronate Sodium | 29 | $211 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in York
- Daniel Efiom-EkahaYork$346K
- Chanh HuynhYork$115K
- Dan SotirescuYork$114K
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.